Replies to post #138362 on Biotech Values

[Summer2762]

If you think OBF with Lan DeMets is a necessity/possibility, can there be asymmetrical boundaries for futility and efficacy for this trial? Any hint that the futility boundary was binding? (I am trying to reconcile the missing alpha spent).